Stockscreener 앱 받기
235.70
2.08%
-5.68
전일 마감가:
$241.38
열려 있는:
$238.51
하루 거래량:
316.70K
Relative Volume:
0.44
시가총액:
$14.47B
수익:
$534.57M
순이익/손실:
$-293.67M
주가수익비율:
-47.44
EPS:
-4.968
순현금흐름:
$-187.10M
1주 성능:
+3.22%
1개월 성능:
+8.73%
6개월 성능:
+14.79%
1년 성능:
+51.65%
1일 변동 폭
$234.88
$240.77
1주일 범위
$224.21
$248.60
52주 변동 폭
$124.06
$248.60
Ascendis Pharma A S Adr Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S Adr
|
235.70 | 14.82B | 534.57M | -293.67M | -187.10M | -4.968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.69 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.88 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.44 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
290.22 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-17 | 개시 | Raymond James | Strong Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S Adr 주식(ASND)의 최신 뉴스
This Biopharma Stock Flirts With Buy Point After New FDA Approval - Investor's Business Daily
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 - Sahm
Ascendis Wins FDA Approval For Rare Disease Therapy - Sahm
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference - Sahm
Ascendis Pharma NasdaqGS ASND Revenue Surge Keeps Losses In Focus And Tests Bullish Narratives - Sahm
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - GlobeNewswire Inc.
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - Sahm
Ascendis Pharma (ASND) Is Up 5.2% After Revenue Jumps And Losses Narrow In 2025 Results - Sahm
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize
Ascendis Pharma (ASND) Revenue Nearly Doubles to 720M in 2025 Fueled by Core Product Growth - Finviz
Does Stronger 2025 Results And Narrowing Losses Reshape The Bull Case For Ascendis Pharma (ASND)? - Sahm
Toll Brothers Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - MSN
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Sahm
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript - The Globe and Mail
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss - Chartmill
Ascendis Pharma Earnings Report: Q4 Overview - Sahm
Did Health Canada’s Yorvipath Approval Just Shift Ascendis Pharma’s (ASND) Investment Narrative? - Sahm
Hershey Upgraded, Robinhood Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Assessing Ascendis Pharma (ASND) Valuation After Health Canada Approval For Yorvipath - Sahm
Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT - Finviz
ASCENDIS PHARMA A/SADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum - Chartmill
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Allstate Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Is Positive COACH Data and Priority Review for TransCon CNP Reframing Ascendis Pharma’s (ASND) Investment Case? - Sahm
Ascendis Pharma ADR Hits 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Ascendis Pharma Achondroplasia Data Highlights Emerging Rare Disease Franchise Potential - Sahm
Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Trial Growth And Proportionality Results - Sahm
Ascendis Pharma ADR shows rising price performance with jump to 83 RS rating - MSN
Ascendis Pharma A/S (ASND): A Bull Case Theory - Finviz
Did COACH Trial Combo Data and FDA Priority Review Just Shift Ascendis Pharma's (ASND) Investment Narrative? - Sahm
Ascendis Pharma ADR Shows Rising Price Performance With Jump To 83 RS Rating - Investor's Business Daily
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Phase 2 Achondroplasia Results - Sahm
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - Sahm
Ascendis Pharma ADR reaches 80-plus relative strength rating benchmark - MSN
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan - ChartMill
Ascendis Pharma ADR Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Can you now get a good deal on Ascendis Pharma A/S ADR’s shares? - uspostnews.com
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today - Sahm
Ascendis Pharma’s Price Surge Amid New Developments - StocksToTrade
Looking Into Ascendis Pharma AS's Recent Short Interest - Sahm
Taking on analysts’ expectations and winning: Ascendis Pharma A/S ADR (ASND) - setenews.com
Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades' - Sahm
The time has not yet come to remove your chips from the table: Ascendis Pharma A/S ADR (ASND) - setenews.com
Honda Upgraded, McDonald’s Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Sahm
Ascendis Pharma Reports Third Quarter 2025 Financial Results - Sahm
Ascendis Pharma A S Adr (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.97%
자본화:
|
볼륨(24시간):